You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥-B(02142.HK):百濟神州與映恩生物訂立協議

格隆匯7月14日丨和鉑醫藥-B(02142.HK)發佈公吿,有關(其中包括)與映恩生物製藥(蘇州)有限公司(“映恩生物”)於2022年訂立的合作協議,授予映恩生物其針對特定腫瘤的單克隆抗體的獨家權,以開發全球首創的抗體藥物偶聯物(“ADC”)。百濟神州與映恩生物(諾納生物合作伙伴)訂立協議,以由百濟神州獲得用於治療特定實體瘤患者的在研、臨牀前ADC項目的全球臨牀及商業許可的獨家選擇權。該項目根據合作協議而開發。

2022年,公司通過公司全資附屬公司諾納生物(前身為和鉑醫藥(蘇州)有限公司)與映恩生物訂立合作協議。無論上文所披露的百濟神州協議如何規定,諾納生物與映恩生物之間的合作將根據合作協議的條款繼續進行。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account